Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...
Dr. Hua-Jay Cherng, a hematologist oncologist at NewYork-Presbyterian/Columbia University Medical Center, discussed how ctDNA ...
Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...
Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections ...
– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at ...
Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...
Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results